Search results for: 'Preferred Destination for Early Phase Clinical Trials'

12 May 2025  |  Global  |  Market Research

Clinical Decision Support System Market, Global, 2024–2030

AI Integration is Driving Transformational Growth by Enabling Improvements in Clinical Outcomes

Infographics

×

The increasing focus on effective population health management is prompting healthcare organizations to adopt next-generation clinical decision support tools that drive market growth. Healthcare systems continue to face significant clinical quality and efficiency challenges, leading to a heightened focus on implementing clinical decision support sy...

With the end of the COVID-19 pandemic, healthcare providers have been directing most of their capabilities toward preventive healthcare and precision medicine, as the clinical diagnostics industry continues its transition from a centralized to a decentralized testing model. Globally, 2024 is set to be a profitable year for the industry, which will ...

The COVID-19 pandemic impact on the biopharmaceutical industry has increased patient-centricity and the adoption of eClinical services digital platforms to manage clinical development programs. Capital investments and co-development recorded an uptick over the last 2 years, focusing on advancing clinical assets and expanding the number of Phase 2 a...

This Frost Radar™ investigates the growth and innovation activity of clinical decision support system (CDSS) providers in their pursuit to help end users take the next best medical care action. A CDSS provides professionals with access to organized clinical knowledge integrated with the patient’s medical profile to improve their health and overall ...

The global clinical diagnostics market is poised for strong growth, driven by increased adoption of advanced diagnostics technologies, greater investment in laboratories, and improved access to molecular and immunodiagnostic testing facilities. In 2025, the industry continued its transformation, establishing testing systems as intelligent systems...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

More than 6,000 molecules are currently in clinical development across the pharmaceutical research and development (R&D) landscape, with more than 11,000 in the preclinical phase. The industry is witnessing the growth of small- to mid-segment pharma/biotech players making significant contributions to drug discovery and development pipelines. Across...

06 Jul 2021  |  North America  |  Market Research

Global Decentralized Clinical Trial (DCT) Growth Opportunities

Strategic Partnering and M&A Activity in At-home Monitoring Solutions Gain Momentum

Infographics

×

Frost & Sullivan presents post–COVID-19 growth opportunities and strategic imperatives for the global decentralized clinical trials (DCT) market, covering the markets maturity, key participants, adoption drivers and restraints, and recent mergers and acquisitions. The report identifies initiatives by major global contract research organizations (CR...

Worldwide cancer incidence is expected to exceed 35 million new cases by 2050, a 77% rise from the 20 million cases in 2022. Alcohol intake, tobacco usage, obesity, and air pollution are the main causes of this increase. Cancer studies today emphasize cell and gene therapy, antibody-drug conjugates (ADCs), checkpoint inhibitors, and multi-specific...